Stock SNGX SOLIGENIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Soligenix, Inc.

Equities

SNGX

US8342235053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
4.96 USD -0.03% Intraday chart for Soligenix, Inc. -11.43% -59.06%
May. 23 Sector Update: Health Care Stocks Retreat Late Afternoon MT
May. 23 Sector Update: Health Care Stocks Lower Thursday Afternoon MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
AQ
Soligenix Announces Reverse Stock Split
PR
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
PR
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
PR
Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
PR
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
AQ
Soligenix Encourages Stockholders to Vote Prior to Annual Meeting
PR
Soligenix Announces Recent Accomplishments and First Quarter 2024 Financial Results
AQ
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
PR
Soligenix to Present at Upcoming Conferences
PR
Soligenix Announces Pricing of $4.75 Million Public Offering
PR
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
PR
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
PR
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
PR
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
PR
Soligenix Announces Formation of Beh et s Disease Medical Advisory Board
AQ
Soligenix to Present at The Microcap Conference
PR
FDA Grants Soligenix 'Fast Track' Designation for Dusquetide in the Treatment of Oral Lesions of Behcet's Disease
AQ
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
PR
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SNGX Stock
  4. News Soligenix, Inc.
  5. Press Releases